What to expect.
- Dual-receptor mechanism (GIP and GLP-1) that supports appetite regulation and insulin response
- Studied in the large SURMOUNT and SURPASS clinical trial programs
- Once-weekly subcutaneous injection
- May support blood sugar control alongside weight management
- Prescribed and monitored by a physician as part of an individualized plan
Dr. Taylor's take
“Tirzepatide's dual-agonist mechanism, hitting both GIP and GLP-1, tends to produce stronger appetite and metabolic effects than GLP-1 alone for many patients. I prescribe it after a full medical intake, start at a low dose, and titrate slowly to manage the gastrointestinal side effects that are most common early on. It works best as part of a plan that includes nutrition and activity, not on its own.”
Dr. Patrick Taylor, MD · Live Vital physician
About Tirzepatide.
Also known as: Mounjaro, Zepbound, LY3298176
Tirzepatide is a once-weekly injectable that activates two incretin receptors at the same time: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Developed by Eli Lilly, it is also known by the brand names Mounjaro and Zepbound. By engaging both receptors rather than GLP-1 alone, tirzepatide influences appetite, insulin secretion, and the rate at which the stomach empties.
In the SURMOUNT-1 trial, participants without diabetes taking the highest dose lost an average of roughly 20% of their body weight over 72 weeks, alongside a lifestyle program. Live Vital offers tirzepatide as a physician-prescribed therapy after a complete medical intake with Dr. Taylor, who reviews your history and goals and monitors your protocol over time. Outcomes vary by individual and are not guaranteed.
How it works
Tirzepatide is a dual agonist: it binds both the GIP and GLP-1 receptors. GLP-1 activation slows gastric emptying and signals fullness to the brain, so you feel satisfied on less food, while both GIP and GLP-1 improve the body's insulin response to meals. The combined effect is reduced appetite and steadier blood sugar. Because it acts on two complementary pathways rather than one, tirzepatide is described as a dual-agonist, distinguishing it from single-target GLP-1 medications.
Who it may help.
- Adults working on weight management who have not reached their goals with lifestyle changes alone
- People with excess weight who also have blood-sugar concerns
- Those who prefer a once-weekly injection over daily medication
- Patients who want a physician-supervised protocol with ongoing monitoring
What to expect, when.
Doses are increased gradually over the first weeks to reduce side effects, so appetite changes are often noticed early while more meaningful weight change typically builds over several months of consistent use. In clinical trials, weight reduction continued through the 72-week study period. Individual results vary and depend on your health history, dose, and how your body responds under Dr. Taylor's supervision.
Dosing is not one-size-fits-all. Dr. Taylor personalizes your dose and schedule after your medical intake, and adjusts it as your protocol progresses.
Safety information.
Possible side effects
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Decreased appetite
- Abdominal discomfort
- Injection site reactions
Who should talk to us first
- Personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- History of pancreatitis
- Pregnancy or breastfeeding
- Severe gastrointestinal disease
This information is educational and is not a substitute for medical advice. Every protocol requires a medical intake and physician approval, and outcomes vary by individual.
Standard with every plan.
Doctor-prescribed
Prescribed through Live Vital’s licensed clinical team.
Licensed US pharmacy
Prepared by a licensed US pharmacy and shipped to you.
Unlimited messaging
Reach our care team directly with questions at any time.